Red Flags
- Acute urinary retention with renal impairment, infection, or significant distress — same-day catheterisation; trial without catheter on alpha-blocker[1]
- Macroscopic haematuria, suspected prostate cancer (raised PSA, abnormal DRE) — separate diagnostic pathway[1]
- Recurrent UTI, bladder stones, refractory retention, hydronephrosis, or persistent residual >300 mL — surgical indication[1]
- Severe LUTS with renal impairment or acute on chronic retention — admit; avoid rapid decompression (post-obstructive diuresis)[1]
First-line treatment
Interventions
- Watchful waiting + lifestyle for mild symptoms[1]Reduce evening fluids, avoid caffeine and alcohol after evening, double voiding, bladder retraining, manage constipation; effective for IPSS ≤7
- Combination medical therapy for moderate-severe symptoms[1]Alpha-blocker for symptom relief; add 5-alpha-reductase inhibitor for prostates >40 mL; combine with antimuscarinic or beta-3 agonist for OAB component; tadalafil 5 mg daily for combined LUTS+ED
- Minimally invasive surgical therapy[1]Prostatic urethral lift, water vapour thermal therapy (Rezum), aquablation, prostate artery embolisation; outpatient or short-stay options for selected men
- Standard surgical procedures[1]TURP — gold standard for prostates 30–80 mL. Holmium laser enucleation (HoLEP) — size-independent, lower bleeding. Photoselective vaporisation (GreenLight) — useful in anticoagulated. Simple prostatectomy — large prostates >80–100 mL
First-line drug therapy
| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Tamsulosin or silodosin (alpha-blocker)[1] | Selective alpha-1A adrenergic blocker | Tamsulosin 0.4 mg PO daily; silodosin 8 mg PO daily; alfuzosin XL 10 mg PO daily | — | First-line symptomatic; rapid onset; orthostatic hypotension; intraoperative floppy iris syndrome — inform ophthalmologist before cataract surgery |
| Finasteride or dutasteride (5-ARI)[1] | 5-alpha-reductase inhibitor | Finasteride 5 mg PO daily; dutasteride 0.5 mg PO daily | — | Add to alpha-blocker for prostate >40 mL; takes 6–12 months for full effect; reduces PSA by ~50% (interpret cancer screening); sexual side effects; teratogen |
| Tadalafil 5 mg (LUTS + ED)[1] | PDE5 inhibitor | 5 mg PO once daily | — | Daily-dose tadalafil approved for combined LUTS and ED; do not combine with nitrates |
| Antimuscarinic (solifenacin, tolterodine) for OAB component[1] | Muscarinic antagonist | Solifenacin 5–10 mg PO daily; tolterodine ER 4 mg PO daily | — | Add for OAB symptoms when residual urine acceptable; check PVR before adding (caution if >150 mL); dry mouth, constipation |
| Mirabegron (beta-3 agonist) for OAB component[1] | Beta-3 agonist | 25–50 mg PO daily | — | Alternative to antimuscarinic; lower dry mouth burden; BP elevation; less anticholinergic side effects |
| Desmopressin (nocturnal polyuria)[1] | Vasopressin analogue | 60 µg sublingual nightly (women); 25 µg sublingual nightly (men); titrate | — | Selected nocturnal polyuria refractory to lifestyle; check sodium 1, 7, and 30 days, then 3-monthly; risk of hyponatraemia particularly elderly; avoid in HF, hypoalbuminaemia, anti-diuretic medications |
Tamsulosin or silodosin (alpha-blocker)[1]
Selective alpha-1A adrenergic blocker
- Adult
- Tamsulosin 0.4 mg PO daily; silodosin 8 mg PO daily; alfuzosin XL 10 mg PO daily
- Paediatric
- —
First-line symptomatic; rapid onset; orthostatic hypotension; intraoperative floppy iris syndrome — inform ophthalmologist before cataract surgery
Finasteride or dutasteride (5-ARI)[1]
5-alpha-reductase inhibitor
- Adult
- Finasteride 5 mg PO daily; dutasteride 0.5 mg PO daily
- Paediatric
- —
Add to alpha-blocker for prostate >40 mL; takes 6–12 months for full effect; reduces PSA by ~50% (interpret cancer screening); sexual side effects; teratogen
Tadalafil 5 mg (LUTS + ED)[1]
PDE5 inhibitor
- Adult
- 5 mg PO once daily
- Paediatric
- —
Daily-dose tadalafil approved for combined LUTS and ED; do not combine with nitrates
Antimuscarinic (solifenacin, tolterodine) for OAB component[1]
Muscarinic antagonist
- Adult
- Solifenacin 5–10 mg PO daily; tolterodine ER 4 mg PO daily
- Paediatric
- —
Add for OAB symptoms when residual urine acceptable; check PVR before adding (caution if >150 mL); dry mouth, constipation
Mirabegron (beta-3 agonist) for OAB component[1]
Beta-3 agonist
- Adult
- 25–50 mg PO daily
- Paediatric
- —
Alternative to antimuscarinic; lower dry mouth burden; BP elevation; less anticholinergic side effects
Desmopressin (nocturnal polyuria)[1]
Vasopressin analogue
- Adult
- 60 µg sublingual nightly (women); 25 µg sublingual nightly (men); titrate
- Paediatric
- —
Selected nocturnal polyuria refractory to lifestyle; check sodium 1, 7, and 30 days, then 3-monthly; risk of hyponatraemia particularly elderly; avoid in HF, hypoalbuminaemia, anti-diuretic medications
Safety-net
- Avoid sudden stopping of alpha-blocker before cataract surgery — tell your ophthalmologist about the medication[1]
- Inability to pass urine, severe lower abdominal pain or distension — same-day medical review for catheterisation[1]
- On 5-ARI: PSA halves over 6–12 months; if any rise from new nadir, investigate for prostate cancer[1]
Referral criteria
- Acute or chronic retention not relieved by trial without catheterUrology[1]
- Recurrent UTI, bladder stones, hydronephrosis, or persistent residual >300 mLUrology for surgical evaluation[1]
- Suspected prostate cancerUrology with multiparametric MRI prostate[1]
- Failure of medical therapy after 3–6 months at adequate doseUrology for surgical / MIST evaluation[1]
Clinical summary
Diagnosis and stepwise medical and surgical management of male non-neurogenic lower urinary tract symptoms attributed to BPH per EAU guidance.